Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that can have a significant impact on patient health and quality of life (QoL). Roughly one-third of AD patients have severe disease that requires systemic treatment directed at controlling immune responses, but many clinicians are unfamiliar with new and emerging agents that target the underlying pathophysiology of AD and with the related mechanisms of action and safety and efficacy profiles. To provide allergists and dermatologists with up-to-date information on management of moderate-to-severe AD, Rockpointe and the Potomac Center for Medical Education offer a free CME/MOC/MIPS program available as an enduring webcourse until April 26, 2023.
The landscape of AD treatment is changing rapidly, with a number of recently approved agents and many others in late-stage trials that target the inflammatory processes underlying AD. To deliver optimal care to their patients, dermatologists and allergists need to be aware of these processes and agents, such as Janus kinase inhibitors (JAKi) and therapies that target the over-expression of Th2 cytokines. Routine and regular assessment of disease severity is essential to AD management, but clinicians often underestimate disease severity and the impact on patients’ quality of life, leading to undertreatment.
A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis is an hour-long activity geared toward allergists and dermatologists who manage patients with moderate to severe AD. Program topics include the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term. Presenters will also address assessment tools and strategies for identifying disease severity, and will stress the importance of patient engagement and communicating the need for treatment adherence.
At the program’s conclusion, participants should be able to:
- Discuss type 2 inflammatory processes and related physiologic pathways underlying atopic dermatitis pathophysiology.
- Identify patients with moderate to severe atopic dermatitis using evidence-based assessment tools.
- Individualize atopic dermatitis action plans based on the goals and needs of the patient using a shared decision-making approach.
- Evaluate the safety and efficacy of current and emerging targeted therapies for moderate to severe atopic dermatitis.
This program is accredited for ACCME Continuing Medical Education, American Board of Dermatology Maintenance of Certification, and Centers for Medicare and Medicaid Services (CMS) MIPPS credit and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by an educational grant from Pfizer and is jointly provided by the Potomac Center for Medical Education and Rockpointe, with patient resources provided by the National Eczema Association. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing medical education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
TTo view the enduring webcourse, click here.